SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
STSA Stock Price Chart Interactive Chart >
STSA Price/Volume Stats
| Current price | $0.94 | 52-week high | $8.08 |
| Prev. close | $0.95 | 52-week low | $0.59 |
| Day low | $0.93 | Volume | 167,671 |
| Day high | $0.98 | Avg. volume | 142,159 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $3.74 | Market Cap | 30.98M |
SATSUMA PHARMACEUTICALS, INC. (STSA) Company Bio
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Latest STSA News From Around the Web
Below are the latest news stories about SATSUMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate STSA as an investment opportunity.
Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For ApprovalSatsuma Pharmaceuticals Inc (NASDAQ: STSA ) provided an update on its STS101 development program and corporate update. Further analysis of results from the recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating and sustained antimigraine effects on clinically critical secondary endpoints. Satsuma believes the results … Full story available on Benzinga.com |
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate UpdateFurther analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpointsQualitative and quantitative primary market research conducted post-SUMMIT trial readout and incorporating updated STS101 profile consistent with SUMMIT trial results indicates headache specialists continue to have strong interest in STS101, with high prescribers o |
Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) Shares Surged 7.79% In A Week – But Can It Maintain Its Gains?In last trading session, Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) saw 0.57 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.94 trading at $0.16 or 19.87% at ring of the bell on the day assigns it a market valuation of $30.73M. That closing price of STSA’s stock is … Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) Shares Surged 7.79% In A Week – But Can It Maintain Its Gains? Read More » |
As Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gains 14%, insiders who bought last year may be wishing they had bet higherInsiders who bought Satsuma Pharmaceuticals, Inc. ( NASDAQ:STSA ) stock in the last 12 months were richly rewarded last... |
Volume Buzzers: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), Asensus Surgical, Inc. (AMEX:ASXC)Satsuma Pharmaceuticals, Inc. (STSA) with the stream of 1.77 also noticed, India Asensus Surgical, Inc. (ASXC) encountered a rapid change of 0.95 in the last hour of Monday’s trading session. … The post Volume Buzzers: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), Asensus Surgical, Inc. (AMEX:ASXC) appeared first on Stocks Equity . |
STSA Price Returns
| 1-mo | 4.44% |
| 3-mo | -80.89% |
| 6-mo | -80.50% |
| 1-year | -82.10% |
| 3-year | -96.20% |
| 5-year | N/A |
| YTD | 4.44% |
| 2022 | -80.00% |
| 2021 | -2.39% |
| 2020 | -76.58% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...